MediPaper Hong Kong

Medical &Health News

Therapeutic Areas

ONCOLOGY ARTICLES

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

24th January 2020

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

ADDING RIBOCICLIB TO FULVESTRANT IMPROVES THE SURVIVAL OF ADVANCED BREAST CANCER PATIENTS MONALEESA-3

12th January 2020

Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

12th June 2019

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

3rd June 2019

ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

KEYNOTE-158 pembrolizumab in previously treated advanced cervical cancer

24th April 2019

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

Atezolizumab with or without cobimetinib vs regorafenib for previously treated metastatic colorectal cancer IMblaze370

22nd April 2019

Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

9th March 2019

US FDA approved immune-checkpoint inhibitors updated 09-Mar-2019

腫瘤學新知 | CANCER INFORMER HONG KONG

Therapeutic Areas

MEMBERS ONLY

irAE immune-related adverse events immune-mediated adverse events hepatitis pneumonitis rash diabetes_small

©invincible7 / 123RF Stock Photo

CONFERENCE HIGHLIGHTS

ESMO-2018-ESMO18-pembrolizumab-nivolumab-durvalumab-atezolizumab-avelumab-ipilimumab-tremelimumab-osimertinib-cabozantinib-lenvatinib-lorlatinib

©European Society for Medical Oncology

ECTRIMS2018 multiple sclerosis MS neurology

©ECTRIMS

ASCO 2018 ASCO18 pembrolizumab nivolumab durvalumab atezolizumab avelumab ipilimumab tremelimumab olaparib rucaparib niraparib PARP palbociclib ribociclib abemaciclib CDK46 osimertinib cabozantinib lenvatinib lorlatinib

©American Society for Clinical Oncology (ASCO)

aacr2018 american association for cancer research annual meeting 2018 AACR 2018 AACR annual meeting 2018

©American Association for Cancer Research

CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology

©Chinese Society for Anesthesiology

© European Society for Medical Oncology

ANAESTHESIOLOGY.ASIA

Medipaper Medical Communications Ltd Anaesthesiology anaesthesiology.asia anaesthesiology news asia ERAS TIVA

©sherryyates / 123RF Stock Photo

ONCOLOGY ARTICLES (Cont’d)

Immunoncology I-O drugs and immunotherapy for renal cancer RCC

5th March 2019

Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

The treatment of advanced and metastatic renal cell carcinoma (RCC) is at the forefront of yet another revolution. Just over a decade ago, vascular endothelial growth factor receptor (VEGFR) targeting agents such as sunitinib radically changed the treatment paradigm of RCC and have become the standard-of-care with a median overall survival (OS) nearing 30 months. Now, immunotherapy with immune checkpoint inhibitors (ICIs) is rapidly changing the treatment algorithms for patients with advanced kidney cancer.

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

16th January 2019

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

5th December 2018

MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

4th December 2018

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

Robert Lewandowski Y90 TARE TheraSphere The Emerging Role of Yttrium90 in Primary and Metastatic Liver Cancer hepatocellular carcinoma hcc

22nd November 2018

The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

21st November 2018

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

ESMO 2018 HCC ESMO18 Liver Cancer ESMO2018 hepatocellular carcinoma hepatobiliary cholangiocarcinoma BTC

3rd November 2018

ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

31st October 2018

Management of Immune-Mediated Hepatitis: a Case Report

innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

15th October 2018

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

11th October 2018

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

26th April 2019

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

UPPSALA, Sweden, April 24, 2019 /PRNewswire/ -- Researchers of the Erasmus University Medical Center in Rotterdam − the Netherlands, consider that the synthetic and fully resorbable TIGR® Matrix surgical mesh (Novus Scientific AB, Uppsala − Sweden) may reduce frequent risks related to the surgical repair of Sportsman's hernia.

ERAS guidelines for antenatal and preoperative care in caesarean delivery 1

21st January 2019

ERAS guidelines for antenatal and preoperative care in caesarean delivery

Dr Paul Kessler - Euroanaesthesia 2018 - Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements

©Aspen Pharmacare

26th December 2018

Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements

Dr Ngai LIU - Euroanaesthesia 2018 - Closed-Loop or Automated Titration of IV Anaesthesia Impact on Routine Anaesthesia

©Aspen Pharmacare

25th December 2018

Closed-Loop or Automated Titration of IV Anaesthesia: Impact on Routine Anaesthesia

Efficacy of Oral Cladribine in Multiple Sclerosis Durable after a 2-Year Course of Treatment

3rd December 2018

Efficacy of oral Cladribine for MS durable after a two-year treatment course

Meta-analysis TIVA with propofol lowers post-operative nausea, vomiting, and pain

27th November 2018

Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy

©MediPaper Medical Communications Ltd

22nd November 2018

Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy

Prof. Stephen Chan i-o-immunooncology-nivolumab-immunotherapy-hcv-hbv-reactivation-hepatitis-b-hepatitis-c-carrier

18th November 2018

I-O in Special Populations: Chronic Viral Hepatitis Carriers

Early treatment with ocrelizumab lowers 5-year brain atrophy-rates in MS

25th October 2018

Early treatment with ocrelizumab lowers 5-year brain atrophy rates in MS

TAVR transcatheter aortic valve replacement with Portico valve reduces severe aortic stenosis in real-world study PORTICO-1

28th September 2018

Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study

15th May 2019

Venetoclax FDA approved for CLL and SLL

On 15 May 2019, the FDA approved venetoclax (Venclexta®, AbbVie/Genentech) for the treatment of adult chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) patients.

14th May 2019

FDA approves avelumab plus axitinib for renal cell carcinoma

10th May 2019

Ramucirumab FDA approved for hepatocellular carcinoma

3rd May 2019

T-DM1 FDA approved for early breast cancer

2nd May 2019

Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation

26th April 2019

Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients

22nd April 2019

Palbociclib approved for the treatment of male breast cancer

22nd April 2019

Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

18th April 2019

Single-agent pembrolizumab FDA approved for the first-line treatment of stage III NSCLC with PD-L1 TPS ≥1%

23rd March 2019

Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

© Copyright – MediPaper Medical Communications – Medical Communications & Health News